Addition of either inhibitors alone resulted in modest increase in BMPRII expression (data not shown); however, the expression levels of BMPRII in SSc-MVECs increased and reached normal levels when both were added to cell cultures (levels increased from 0.26 ± 0.03 to 0.96 ± 0.05; P < 0.01, SSc-MVECs untreated control versus Aza-TSA-treated SSc-MVECs), while no effects on BMPRII expression levels were noted in control-MVECs (Fig. 6). The gene discussed is BMPR2; the disease is systemic sclerosis.